Catabasis Pharmaceuticals (CATB) CEO, Jill Milne on Q2 2019 Results - Earnings Call Transcript

Catabasis Pharmaceuticals Inc. (CATB) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET

Company Participants

Jill Milne - Chief Executive Officer
Noah Clauser - Vice President, Finance
Joanne Donovan - Senior Vice President, Clinical Development, Chief Medical Officer
Andrew Nichols - Chief Scientific Officer
Andrea Matthews - Vice President, Corporate Affairs

Conference Call Participants

Hartaj Singh - Oppenheimer
Joel Beatty - Citi

Operator

Good day ladies and gentlemen and welcome to the Q2 2019 Catabasis Pharmaceuticals Inc. Earnings conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question and answer session and instructions will be given at that time. If anyone should require operator assistance during the conference, please press star then zero on your telephone keypad.

I would now like to turn the call over to Andrew Matthews, Vice President, Corporate Affairs. Ma’am, you may begin.

Andrea Matthews

Thank you Sydney. Welcome to today’s Catabasis Pharmaceuticals conference call where we will provide a corporate update and review our second quarter 2019 financial results. With me today are Jill Milne, Chief Executive Officer; Joanne Donovan, Chief Medical Officer;’ Andrew Nichols, Chief Scientific Officer; and Noah Clauser, Vice President of Finance.

We issued a press release this morning summarizing our corporate update and our Q2 2019 financial results, which we will reference on today’s call and is available on our website. We are also using slides during today’s call that are available within the Events and Presentations section in the Investors part of our website.

I would like to note that during today’s call, as mentioned on Slide 2, we will be making statements related to our business based on current and future expectations that may be considered forward-looking statements under federal securities laws. Actual results may differ materially from those indicated by these